Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1859MR)

This product GTTS-WQ1859MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1859MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5399MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ10340MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ11721MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15177MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ3972MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ7209MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ12972MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11235MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW